Expansion opportunities Catawba Research has been actively expanding its leadership and advisory footprint in 2023-2024, including appointments of a new COO and head of Project Management, and expansion of its Scientific Advisory Board. This suggests a strategic flexibility and capacity to take on larger, more complex trials and enhanced governance services for sponsors seeking robust CRO partnerships.

Partnership leverage Recent collaborations with Bingli Inc. to streamline patient pre-screening and Elligo Health Research to expand access indicate a strong emphasis on site network optimization and patient recruitment. Target opportunities include sponsors prioritizing efficient enrollment, broader site access, and integrated patient screening capabilities.

Therapeutic and device focus As a full-service CRO serving pharmaceutical, device, formulation development and biotech clients, Catawba Research positions itself to support cross-discipline programs, including device trials and complex formulations. This broad service scope opens cross-sell opportunities across multiple product types within sponsor portfolios.

Mid-market potential With a revenue range of 10M-25M and a lean employee base relative to mega-CROs, Catawba Research appears well-suited for mid-market sponsors seeking high-touch, cost-effective, agile trial management. Sales conversations can emphasize personalized service, flexibility, and rapid decision cycles.

Strategic alliances The company already maintains a deep network of partnerships and affiliations and has shown intent to grow through advisory and leadership enhancements. This indicates a propensity for co-development, strategic alliances, and preferred provider arrangements that can be pitched to sponsors seeking long-term CRO collaborations with governance and continuity.